Table 2.
Echocardiography Results and Associated Outcomes and Risk Factors
| Elevated RV Pressure (n = 13) |
Normal RV Pressure (n = 87) |
P | PEF (n = 17) |
No PEF (n = 83) |
P | Decreased LV Function (n = 3) |
Normal LV Function (n = 97) |
P | |
|---|---|---|---|---|---|---|---|---|---|
| aGVHD (n = 33) | 2 (15%) | 31 (36%) | .210 | 6 (35%) | 27 (32%) | 1.000 | 3 (100%) | 30 (31%) | .034 |
| cGVHD (n = 4) | 1 (8%) | 3 (3%) | .432 | 0 | 4 (5%) | 1.000 | 0 | 4 (4%) | 1.000 |
| VOD (n = 1) | 0 | 1 (1%) | 1.000 | 0 | 1 (1%) | 1.000 | 0 | 1 (1%) | 1.000 |
| TA-TMA (n = 32) | 9 (69%) | 23 (26%) | .004 | 9 (52%) | 23 (28%) | .051 | 0 | 32 (33%) | .549 |
| BK virus (n = 36) | 5 (39%) | 31 (36%) | 1.000 | 10 (59%) | 26 (31%) | .050 | 3 (100%) | 33 (34%) | .044 |
| Adenovirus (n = 19) | 1 (8%) | 18 (21%) | .452 | 6 (35%) | 13 (16%) | .086 | 1 (33%) | 18 (19%) | .472 |
| CMV (n = 25) | 2 (15%) | 23 (26%) | .508 | 5 (29%) | 20 (24%) | .759 | 1 (33%) | 24 (25%) | 1.000 |
| EBV (n = 41) | 6 (46%) | 35 (40%) | .766 | 6 (35%) | 35 (42%) | .788 | 2 (67%) | 39 (40%) | .566 |
| Severe hypertension (n = 25) | 6 (46%) | 20 (23%) | .094 | 7 (41%) | 19 (23%) | .136 | 2 (66%) | 24 (25%) | .165 |
| Oxygen during first 100 d (n = 33) | 10 (77%) | 23 (26%) | .001 | 9 (53%) | 24 (29%) | .087 | 1 (33%) | 32 (33%) | .984 |
| Respiratory failure (n = 22) | 4 (31%) | 18 (21%) | .475 | 7 (41%) | 15 (18%) | .053 | 1 (33%) | 21 (22%) | .530 |
| 1-Year TRM (n = 15) | 3 (23%) | 12 (14%) | .407 | 4 (24%) | 11 (13%) | .279 | 0 | 15 (16%) | 1.000 |
| Death in first year (n = 24) | 5 (39%) | 19 (22%) | .293 | 6 (35%) | 18 (22%) | .231 | 1 (33%) | 23 (24%) | .565 |
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; VOD, veno-occlusive disease; CMV, cytomegalovirus; EBV, Epstein-Barr virus; TRM, transplant-related mortality.
Outcome associations: elevated RV pressure, PEF, and LV dysfunction. Statistics were performed with Wilcoxon ranked sums test and Fisher exact test.